NCT05004610 Hypertonic Lactate After Cardiac Arrest
| NCT ID | NCT05004610 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Erasme University Hospital |
| Condition | Cardiac Arrest |
| Study Type | INTERVENTIONAL |
| Enrollment | 125 participants |
| Start Date | 2025-02-19 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 125 participants in total. It began in 2025-02-19 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is intended to test the hypothesis that sodium lactate infusion after resuscitation from a cardiac arrest will decrease the magnitude of brain damage, as measured by the serum biomarker concentration of NSE.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years old * Sustained (\> 20 minutes) return of spontaneous circulation (ROSC) * Comatose (GCS \< 9) * Time to ROSC \> 15' Exclusion Criteria: * Protected categories (Pregnant women) * Anticipated withdrawal of support within 24 hours * Traumatic cause of cardiac arrest * Body weight at admission \> 120Kg
Contact & Investigator
Filippo Annoni, MD
PRINCIPAL INVESTIGATOR
Erasme University Hospital
Frequently Asked Questions
Who can join the NCT05004610 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Arrest. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05004610 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05004610 currently recruiting?
Yes, NCT05004610 is actively recruiting participants. Contact the research team at filippo.annoni@erasme.ulb.ac.be for enrollment information.
Where is the NCT05004610 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT05004610 clinical trial?
NCT05004610 is sponsored by Erasme University Hospital. The principal investigator is Filippo Annoni, MD at Erasme University Hospital. The trial plans to enroll 125 participants.